<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901364</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI064</org_study_id>
    <nct_id>NCT04901364</nct_id>
  </id_info>
  <brief_title>Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)</brief_title>
  <acronym>IPMN</acronym>
  <official_title>Sensitivity and Specificity Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma&#xD;
      with pejorative prognosis.&#xD;
&#xD;
      IPMNs require characterization to clarify their potential for degeneration. Clinical and&#xD;
      morphological risk factors for degeneration determine the monitoring rate and the indication&#xD;
      for pancreatic surgery.&#xD;
&#xD;
      Pancreatic surgery remains invasive with high morbidity and mortality rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monoservice and monocentric retrospective study at the Nancy CHRU. We will study&#xD;
      the risk factors for IPMNs degeneration in order to determine the most sensitive and&#xD;
      specific.&#xD;
&#xD;
      To do this, we will use high-grade dysplasia or invasive cancer on the histological analysis&#xD;
      of surgical specimens as the primary endpoint.&#xD;
&#xD;
      The study population will be patients with Branch Duct, Main Duct or mixed IPMNs operated at&#xD;
      the Nancy CHRU between September 2009 and October 2021.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>High-grade dysplasia or invasive cancer</measure>
    <time_frame>12 years</time_frame>
    <description>High-grade dysplasia or invasive cancer on histological analysis of the surgical specimen</description>
  </primary_outcome>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sensitivity and specificity of risk factors for degeneration of IPMNs</intervention_name>
    <description>Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between&#xD;
        September 2009 and October 2021&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU&#xD;
             between September 2009 and October 2021, adults and without legal protection measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IPMNs not operated&#xD;
&#xD;
          -  Pancreatic cancer without IPMNs&#xD;
&#xD;
          -  Patients whose state of health contraindicates pancreatic surgery&#xD;
&#xD;
          -  Non-adult patient&#xD;
&#xD;
          -  Patients under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Baptiste JC CHEVAUX</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Regional Universitaire de Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Remy RF FONTANIE</last_name>
    <phone>0616297216</phone>
    <email>remyfontanie@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion MS SCHAEFER</last_name>
    <phone>0642743330</phone>
    <email>m.schaefer@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jean-Baptiste CHEVAUX</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Baptiste JC CHEVAUX</last_name>
      <phone>0677066140</phone>
      <email>jb.chevaux@chru-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Remy RF FONTANIE</last_name>
      <phone>0616297216</phone>
      <email>r.fontanie@chru-nancy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Baptiste JC CHEVAUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remy RF FONTANIE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion MS SCHAEFER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Jean-Baptiste CHEVAUX</investigator_full_name>
    <investigator_title>PH</investigator_title>
  </responsible_party>
  <keyword>IPMNs</keyword>
  <keyword>Intraductal Papillary Mucinous Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

